First win for J&J over alleged ineffective medicine

Johnson & Johnson has won a soft class closure in the class action against it accusing the pharma giant of knowingly selling a medication that was ineffective.

The ruling by Federal Court Justice Mark Moshinksy means only people registered with the class action led by Baden Green by a certain deadline can take part in a possible settlement. Failing a settlement, the class re-opens and everyone is included again.

The class action covers 21 cold and flu medication sold under the Benadryl, Codral, and Sudafed brand names, now owned by Kenvue, with claims the active ingredient phenylephrine is ineffective.

To see the whole article please log in.

James Quintana Pearce

Log in with your member email for full access.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Email

Retype password

Not a member? Sign up here